Buy Deprenorm MB pills 35 mg 60 pcs
  • Buy Deprenorm MB pills 35 mg 60 pcs


1045 Items
Dosage form
Brand & Manufacturer
Package Size
  • done All payments are SSL encrypted
  • done Full Refund if you haven't received your order
  • done International shipping to the USA, UK and Europe

Clinical Pharmacology


It has an antihypoxic effect. Trimetazidine prevents the decrease in intracellular concentration of adenosine triphosphate (ATP) by maintaining the energy metabolism of cells in a state of hypoxia. Thus, the drug ensures the normal functioning of membrane ion channels, transmembrane transfer of potassium and sodium ions and the preservation of cellular homeostasis. Trimetazidine inhibits fatty acid oxidation by selectively inhibiting the enzyme 3-ketoacyl-CoA thiolase (3-CAT) mitochondrial long-chain fatty acid isoform, which leads to increased glucose oxidation and accelerated glycolysis with glucose oxidation, which causes myocardial protection against ischemia. Switching energy metabolism from fatty acid oxidation to glucose oxidation underlies the pharmacological properties of trimetazidine.

It was experimentally confirmed that trimetazidine has the following properties:

  • supports energy metabolism of the heart and neurosensory tissues during ischemia;
  • reduces the severity of intracellular acidosis and changes in transmembrane ion flow arising from ischemia;
  • reduces the level of migration and infiltration of polynuclear neutrophils in ischemic and reperfused cardiac tissues;
  • reduces the size of myocardial damage;
  • It has no direct effect on hemodynamic parameters.

In patients with angina pectoris, trimetazidine:

  • increases coronary reserve, thereby slowing the onset of ischemia caused by exercise, starting from the 15th day of therapy;
  • limits blood pressure fluctuations caused by exercise, without significant changes in heart rate;
  • reduces the frequency of strokes and the need for short-acting nitroglycerin;
  • improves the contractile function of the left ventricle in patients with ischemic dysfunction.


After ingestion, trimetazidine is absorbed from the gastrointestinal tract and reaches a maximum plasma concentration in about 5 hours. Over 24 hours, plasma concentration remains at a level in excess of 75% of the concentration determined after 11 hours. The equilibrium state is reached after 60 hours. Eating does not affect the bioavailability of trimetazidine.

The volume of distribution is 4.8 l / kg, which indicates a good distribution of trimetazidine in the tissues (the degree of binding to plasma proteins is rather low, about 16% in vitro). Trimetazidine is excreted mainly by the kidneys, mainly unchanged. The kidney clearance of trimetazidine correlates directly with creatinine clearance (CK), hepatic clearance decreases with the patient's age.


- Ischemic heart disease: prevention of angina attacks (in combination therapy);


1 tablet of the prolonged action, film coated, contains:

Active ingredient: Trimetazidine dihydrochloride 35 mg.

Excipients: calcium hydrophosphate dihydrate, microcrystalline cellulose, colloidal silicon dioxide (aerosil), hydroxypropyl cellulose Klucel LF, hydroxypropylmethyl cellulose, plasdone S-630, magnesium stearate.

The composition of the film shell: Selyout (hydroxypropylmethylcellulose, plasdone S-630, polyethylene glycol, talc, ferric oxide red, titanium dioxide).

Trimetazidine is marketed under different brands and generic names, and comes in different dosage forms:

Brand nameManufacturerCountryDosage form
Trimetazidine MB pills
Preductal OD Pharmstandard Russia capsules
Trimetazidine Teva Israel pills
Deprenorm MB Canonpharma Russia pills
Antisten Ozon Russia pills
Rimecor MW Nizhpharm Russia pills
Trimetazidine-Teva Teva Israel pills
Trimetazidine Canonpharma Russia pills
Predizin Gedeon Richter Hungary pills
Trimectal MV Vertex Russia pills
Angiozil retard Replepharm Macedonia pills
Rimecor Nizhpharm Russia pills
Preductal MR Servier Russia pills

No customer reviews for the moment.

Write your review

Write your review


Dosage and Administration

Inside, while eating.

Depren® MB take 1 tablet of 70 mg 1 time per day (in the morning). The course of treatment is recommended by the doctor.

Adverse reactions

The frequency of side effects noted when taking trimetazidine is given in the following gradation:

  • very often (more than 1/10);
  • often (more than 1/100, less than 1/10);
  • infrequently (more than 1/1000, less than 1/100);
  • rarely (more than 1/10000, less than 1/1000);
  • very rarely (less than 1/10000, including individual messages);
  • unspecified frequency (frequency cannot be calculated from available data).

From the side of the central nervous system: often - dizziness, headache. Unspecified frequency - symptoms of parkinsonism (tremor, akinesia, increased tone), instability in the Romberg position and "shaky" gait, restless legs syndrome, other related motor disorders, usually reversible after cessation of therapy. Sleep disturbances (insomnia, drowsiness).

Since the cardiovascular system: rarely - orthostatic hypotension, "flush" of blood to the skin of the face, feeling of heartbeat, extrasystole, tachycardia, marked reduction in blood pressure.

On the part of the circulatory and lymphatic systems: unspecified frequency - agranulocytosis, thrombocytopenia, thrombocytopenic purpura.

On the part of the digestive system: often - abdominal pain, diarrhea, dyspepsia, nausea, vomiting. Unspecified frequency - constipation.

On the part of the liver and biliary tract: unspecified frequency - hepatitis.

For the part of the skin: often - skin rash, itching, hives. Unspecified frequency - acute generalized exantmatous pustus, angioedema.

General disorders: often - asthenia.

With care: patients with severe liver failure (clinical data are limited); patients with impaired renal function (creatinine clearance more than 30 ml / min.); patients over 75 years old.

Drug interactions

There are no data on the interaction with other drugs.

Pregnancy and Lactation

Data on the use of the drug Deprenorm® MV in pregnant women are missing. Animal studies have not revealed direct or indirect reproductive toxicity. Reproductive toxicity studies did not show the effect of trimetazidine on reproductive function in rats of both sexes. The drug is contraindicated in pregnancy due to the lack of clinical data on the safety of its use.

Data on the allocation of trimetazidine or its metabolites in breast milk are not available. The risk for the newborn / child cannot be excluded. Do not use the drug Deprenorm® MV during breastfeeding.

Special instructions

Depren® MB is not intended for the relief of strokes, for the initial course of treatment of unstable angina or myocardial infarction, as well as in preparation for hospitalization or during its first days.

In the case of an attack of angina, treatment should be reviewed and adapted (drug therapy or revascularization).

The drug can cause or worsen parkinsonism symptoms (tremor, akinesia, increased tone), therefore, patients should be regularly monitored, especially the elderly. When motor disorders such as parkinsonism symptoms, restless legs syndrome, tremor, instability in the Romberg position and shakiness of the gait occur, deprenorm® MV should be permanently reversed.

Such cases are rare and symptoms usually disappear after discontinuation of therapy, in most patients within 4 months after discontinuation of the drug. If the symptoms of parkinsonism persist for more than 4 months after discontinuation of the drug, you should consult a neurologist. Cases of falling associated with instability in the Romberg position and "shaky" gait or hypotension may be noted, especially in patients taking antihypertensive drugs (see the section "Side Effects").

Impact on the ability to drive vehicles and other mechanisms that require high concentration of attention

In connection with the possible development of dizziness and other side effects when using the drug Deprenorm® MB, caution should be exercised when driving vehicles and practicing other potentially dangerous activities that require increased concentration and psychomotor speed.


Only limited information is available on trimetazidine overdose. In case of overdose, symptomatic therapy should be carried out.

  • Active ingredient: Trimetazidine

Studies and clinical trials of Trimetazidine (Click to expand)

  1. Pharmacokinetic profile of a modified release formulation of trimetazidine (TMZ MR 35 mg) in the elderly and patients with renal failure
  2. Attenuation of gentamicin-induced nephrotoxicity: trimetazidine versus N-acetyl cysteine
  3. Synthesis of compounds related to metabolites of trimetazidine in rabbits
  4. Trimetazidine: A new cause for drug-induced parkinsonism?
  5. Kinetic spectrophotometric methods for determination of trimetazidine dihydrochloride
  6. Structure–activity studies on the protection of Trimetazidine derivatives modified with nitroxides and their precursors from myocardial ischemia–reperfusion injury
  7. Sensitive determination of trimetazidine in spiked human plasma by HPLC with fluorescence detection after pre-column derivatization with 9-fluorenylmethyl chloroformate
  8. Sensitive and rapid LC–ESI-MS method for the determination of trimetazidine in human plasma
  9. Carvedilol and trimetazidine attenuates ferric nitrilotriacetate-induced oxidative renal injury in rats
  10. Determination of trimetazidine in biological fluids by gas chromatography-mass spectrometry
  11. Stability indicating HPTLC determination of Trimetazidine as bulk drug and in pharmaceutical formulations
  12. Trimetazidine: stability indicating RPLC assay method
  13. Determination of trimetazidine HCl by adsorptive stripping square-wave voltammetry at a glassy carbon electrode
  14. Acute oral trimetazidine administration increases resting technetium 99m sestamibi uptake in hibernating myocardium
  15. The effect of trimetazidine on intrahepatic cholestasis caused by carmustine in rats
  16. Trimetazidine does not modify blood levels and immunosuppressant effects of cyclosporine A in renal allograft recipients
  17. Effects of trimetazidine in ethanol- and acetic acid-induced colitis: oxidant/anti-oxidant status
  18. Influence of Trimetazidine on the synthesis of complex lipids in the heart and other target organs
  19. Trimetazidine effect on phospholipid synthesis in ventricular myocytes: consequences in α-adrenergic signaling
  20. Metabolic therapy in the treatment of ischaemic heart disease: the pharmacology of trimetazidine
  21. Trimetazidine improves left ventricular function in diabetic patients with coronary artery disease: a double-blind placebo-controlled study
  22. Trimetazidine: Effects on delayed afterdepolarizations (DADs) and upstroke velocity of the action potential
  23. Antiischemic effect of trimetazidine: Enzymatic and electric response in a model of in-vitro myocardial ischemia
  24. Electrocardiographic assessment of trimetazidine antiischemic properties

Customers who bought this product also bought:

8 other products in the same category: